Our partnership offer

We are an experienced RNA technology company dedicated to professionally partnering with pharma and biotech with an emerging or established interest in RNA therapeutics. Our expert team supports start-up, early stage and late-stage projects by using our proprietary platforms across RNA chemistry, LNP formulation, and Process Technology, to drive new pipeline development or resolve manufacturing challenges for our partners.


etherna image

mRNA adjuvants

TriMix and TetraMix are proprietary combinations of mRNAs encoding for immune stimulatory proteins that optimally activate dendritic cells to induce vaccine-specific T cells. As such, TriMix and TetraMix can be used to:

  • Enhance efficacy of T-cell vaccines
  • Improve the ex vivo expansion of antigen-specific T cells using TriMix or TetraMix-transfected dendritic cells.
Why partner with us

Flexible partnership

  • Support from design, candidate designation, clinical development to regulatory approval
  • From single indications to
    comprehensive pipeline development

Expert development

  • Dedicated teams committed to meeting your project deadlines
  • Seamless transition through all
    development stages

Integrated offering

  • In-house in-depth chemistry, formulation and manufacturing expertise
  • Single resource for accelerated delivery, no need for multiple partners

To drive discovery and solve challenges for our partners, enabling them to deliver cost-effective,
differentiated, and efficacious RNA therapeutics.

What our customers say
Contact us

Contact us with any queries or for pricing information.